Thyrotropin alfa
- Generic Name
- Thyrotropin alfa
- Brand Names
- Thyrogen
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 194100-83-9
- Unique Ingredient Identifier
- AVX3D5A4LM
- Background
Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein co...
- Indication
For detection of residueal or recurrent thyroid cancer
- Associated Conditions
- Thyroid Cancer
- Associated Therapies
- Radioiodine ablation of thyroid tissue therapy
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CobimetinibProcedure: Computed TomographyProcedure: Diagnostic ImagingProcedure: I-131 Uptake TestRadiation: Iodine I-131Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyBiological: Recombinant Thyrotropin AlfaProcedure: Ultrasound ImagingDrug: Vemurafenib
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT06440850
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-05-28
- Target Recruit Count
- 15
- Registration Number
- NCT06431620
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical Univerity, Nanjing, Jiangsu, China
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06405217
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05668962
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸MedStar Washington Hospital Center, Washington, D.C., District of Columbia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT03244956
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 5
- Registration Number
- NCT02278198
- Locations
- 🇺🇸
Fawn N White, Denver, Colorado, United States
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers with the BRAF Inhibitor Vemurafenib: a Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2014-05-22
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02145143
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Copenhagen University Hospital at Herlev
- Target Recruit Count
- 56
- Registration Number
- NCT00604318
- Locations
- 🇩🇰
Dept of Oncology, Herlev Hospital, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.